MC2 Therapeutics to Present at Upcoming Conferences MC2 Therapeutics to Present at Upcoming Conferences Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within...

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...